AJAllan Johansen

Allan Johansen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Allan Johansen has a total of 202 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Hybrid PET/MRI in major cancers: a scoping review

    by Anni Morsing, Malene Grubbe Hildebrandt, Mie Holm Vilstrup, Sara Elisabeth Wallenius, Oke Gerke, Henrik Petersen, Allan Johansen, Thomas Lund Andersen, Poul Flemming Høilund-Carlsen

    PET/MRI was introduced for clinical use in 2011 and is now an established modality for the imaging of brain and certain pelvic cancers, whereas clinical use for the imaging of other forms of cancer is not yet widespread. We therefore systematically investigated what has been published on the use of PET/MRI compared to PET/CT in the imaging of cancers outside the brain, focusing on clinical areas of application related to diagnosis, staging and restaging.


  • Open Access

    Prospective Comparison of FFR Derived From Coronary CT Angiography With SPECT Perfusion Imaging in Stable Coronary Artery Disease

    by Niels Peter Rønnow Sand, Karsten Tange Veien, Søren Steen Nielsen, Bjarne Linde Nørgaard, Pia Larsen, Allan Johansen, Søren Hess, Lone Deibjerg, Majed Husain, Anders Junker, et al.


  • 15-O-water myocardial flow reserve PET and CT angiography by full hybrid PET/CT as a potential alternative to invasive angiography

    by Anders Thomassen, Poul-Erik Braad, Kasper T. Pedersen, Henrik Petersen, Allan Johansen, Axel C. P. Diederichsen, Hans Mickley, Lisette O. Jensen, Juhani Knuuti, Oke Gerke, et al.

    Combined myocardial flow reserve (MFR) by PET and CT coronary angiography (CTA) is a promising tool for assessment of coronary artery disease. Prior analyses of MFR/CTA has been performed as side-by-side interpretation, not as volume rendered, full hybrid analysis, with fused MFR/CTA. We aimed to: (i) establish a method for full hybrid analysis of MFR/CTA, (ii) validate the inter- and intra-observer reproducibility of MFR values, and (iii) determine the diagnostic value of side-by-side versus full hybrid MFR/CTA with 15-O-water PET. Forty-four outpatients scheduled for invasive coronary angiography (ICA) were enrolled prospectively. All underwent rest/stress 15-O-water PET/CTA with ICA as reference. Within two observers of different experience, the Pearson r at global and territorial level exceeded 0.953 for rest, stress, and MFR values, as determined by Carimas software. Within and between observers, the mean differences between rest, stress, and MFR values were close to zero and the confidence intervals for 95% limits of agreement were narrow. The diagnostic performance of full hybrid PET/CTA did not outperform the side-by-side approach, but performed better than MFR without CTA at vessel level: specificity 93% (95% confidence limits: 89–97%) versus 76% (64–88%), p = 0.0004; positive predictive value 71% (55–86%) versus 51% (37–65%), p = 0.0001; accuracy 90% (84–95%) versus 77% (69–84%), p = 0.0009. MFR showed high reproducibility within and between observers of different experience. The full hybrid model was not superior to side-by-side interpretation of MFR/CTA, but proved better than MFR alone at vessel level with regard to specificity, positive predictive value, and accuracy.


  • Stress-only myocardial perfusion scintigraphy

    by June A. Ejlersen, Ole May, Jesper Mortensen, Gitte L. Nielsen, Jeppe F. Lauridsen, Johansen Allan

    Patients with normal stress perfusion have an excellent prognosis. Prospective studies on the diagnostic accuracy of stress-only scans with contemporary, independent examinations as gold standards are lacking. A total of 109 patients with typical angina and no previous coronary artery disease underwent a 2-day stress (exercise)/rest, gated, and attenuation-corrected (AC), 99m-technetium-sestamibi perfusion study, followed by invasive coronary angiography. The stress datasets were evaluated twice by four physicians with two different training levels (expert and novice): familiar and unfamiliar with AC. The two experts also made a consensus reading of the integrated stress-rest datasets. The consensus reading and quantitative data from the invasive coronary angiography were applied as reference methods. The sensitivity/specificity were 0.92–1.00/0.73–0.90 (reference: expert consensus reading), 0.93–0.96/0.63–0.82 (reference: ≥1 stenosis>70%), and 0.75–0.88/0.70–0.88 (reference: ≥1 stenosis>50%). The four readers showed a high and fairly equal sensitivity independent of their familiarity with AC. The expert familiar with AC had the highest specificity independent of the reference method. The intraobserver and interobserver agreements on the stress-only readings were good (readers without AC experience) to excellent (readers with AC experience). AC stress-only images yielded a high sensitivity independent of the training level and experience with AC of the nuclear physician, whereas the specificity correlated positively with both. Interobserver and intraobserver agreements tended to be the best for physicians with AC experience.


  • Open Access

    Outcome of revascularisation in stable coronary artery disease without ischaemia: a Danish registry-based follow-up study

    by Jane Angel Simonsen, Hans Mickley, Allan Johansen, Søren Hess, Anders Thomassen, Oke Gerke, Lisette O Jensen, Jesper Hallas, Werner Vach, Poul F Hoilund-Carlsen

    Objectives In stable coronary artery disease (CAD), coronary revascularisation may reduce mortality of patients with a certain amount of left ventricular myocardial ischaemia. However, revascularisation does not always follow the guidance suggested by ischaemia testing. We compared outcomes in patients without ischaemia who had either revascularisation or medical treatment. Design and population Based on registries, 1327 consecutive patients with normal myocardial perfusion scintigraphy (MPS) and 278 with fixed perfusion defects were followed for a median of 6.1 years. Most patients received medical therapy alone (Med), but 26 (2%) with a normal MPS and 15 (5%) with fixed perfusion defects underwent revascularisation (Revasc). Outcome measures Incidence rates of all-cause death (ACD) and rates of cardiac death/myocardial infarction (CD/MI). Results With a normal MPS, the ACD rate was 6.2%/year in the Revasc group versus 1.9%/year in the Med group (p=0.01); the CD/MI rates were 6.9%/year and 0.6%/year, respectively (pConclusions With normal MPS, revascularisation conferred a higher risk, even after adjustment for predictors of revascularisation. With fixed defects, the Revascversus Med difference was close to equipoise. Hence, in patients with stable CAD without ischaemia, we could not find evidence to justify exceptional revascularisation.


  • 18F-FDG PET/CT to differentiate malignant necrotic lymph node from benign cystic lesions in the neck

    by Peymaneh Abadi, Allan Johansen, Christian Godballe, Oke Gerke, Poul Flemming Høilund-Carlsen, Anders Thomassen

    Patients presenting with cystic lesions in the neck without obvious signs of malignancy constitute a diagnostic challenge since fine needle aspiration is often insufficient and a diagnosis may not be reached until surgical resection/biopsy is performed. The differential diagnosis of a cystic cervical mass comprises a variety of benign conditions, but malignancy must be ruled out. We examined the diagnostic performance of fluorine-18 fluorodeoxyglucose (18F-FDG) PET/CT to identify malignancy. We retrospectively included consecutive patients referred from the Department of ENT Head and Neck Surgery for 18F-FDG PET/CT-scans because of a solitary neck cyst. Scan results were compared to histopathology and follow-up. The study comprised 58 patients. Twenty patients (34%) were diagnosed with cancer during follow-up. PET/CT suggested malignancy in 34 patients (19 true positive, 15 false positive) and showed no malignancy in 24 (23 true negative, 1 false negative). The sensitivity, specificity, accuracy, positive and negative predictive values were 95% (76–99%), 61% (45–74%), 72% (60–82%), 56% (39–71%), and 96% (80–99%), respectively (95% confidence intervals in brackets). The primary tumor was identified in 14 out of the 20 patients with confirmed cancer. Increased metabolism, as evaluated by PET, was the only imaging characteristic among several others, which associated independently with malignancy in the cystic neck lesions, odds ratio 1.27 (1.07–1.50), p = 0.006. 18F-FDG PET/CT could reliably rule out malignancy (NPV 96%), albeit with a high frequency of false positive scans, requiring further diagnostic work-up. Increased metabolism was the best imaging parameter to differentiate between malignant and benign lesions.


  • Outcome with invasive versus medical treatment of stable coronary artery disease: influence of perfusion defect size, ischaemia, and ejection fraction

    by Jane A. Simonsen, Allan Johansen, Oke Gerke, Hans Mickley, Anders Thomassen, Søren Hess, Charlotte K. Rask, Mohammad Tamadoni, Lisette O. Jensen, Jesper Hallas, et al.

    The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)


  • Open Access

    FDG PET/CT in cancer: comparison of actual use with literature-based recommendations

    by On Behalf Of The Pet/Ct Task Force Of The Region Of Southern Denmark, Henrik Petersen, Paw Christian Holdgaard, Poul Henning Madsen, Lene Meldgaard Knudsen, Dorte Gad, Anders Eggert Gravergaard, Max Rohde, Christian Godballe, Bodil Elisabeth Engelmann, et al.

    Purpose The Region of Southern Denmark (RSD), covering 1.2 of Denmark’s 5.6 million inhabitants, established a task force to (1) retrieve literature evidence for the clinical use of positron emission tomography (PET)/CT and provide consequent recommendations and further to (2) compare the actual use of PET/CT in the RSD with these recommendations. This article summarizes the results. Methods A Work Group appointed a professional Subgroup which made Clinician Groups conduct literature reviews on six selected cancers responsible for 5,768 (62.6 %) of 9,213 PET/CT scans in the RSD in 2012. Rapid Evidence Assessment was applied, using the methodology of systematic reviews with predefined limitations to search PubMed, Embase and the Cochrane Library for articles published in English/Danish/Swedish/Norwegian since 2002. PICO questions were defined, data recorded and quality appraised and rated with regard to strength and evidence level. Consequent recommendations for applications of PET/CT were established. The actual use of PET/CT was compared with these, where grades A and B indicated “established” and “useful” and grades C and D “potentially useful” and “non-recommendable” indications, respectively. Results Of 11,729 citations, 1,729 were considered for review, and 204 were included. The evidence suggested usefulness of PET/CT in lung, lymphoma, melanoma, head and neck, and colorectal cancers, whereas evidence was sparse in gynaecological cancers. The agreement between actual use of PET/CT and literature-based recommendations was high in the first five mentioned cancers in that 96.2 % of scans were made for grade A or B indications versus only 22.2 % in gynaecological cancers. Conclusion Evidence-based usefulness was reported in five of six selected cancers; evidence was sparse in the sixth, gynaecological cancers. Actual use of PET/CT agreed well with recommendations.


  • Open Access

    Quantitative myocardial perfusion by O-15-water PET: individualized vs. standardized vascular territories

    by Anders Thomassen, Henrik Petersen, Allan Johansen, Poul-Erik Braad, Axel Cosmus Pyndt Diederichsen, Hans Mickley, Lisette Okkels Jensen, Oke Gerke, Jane Angel Simonsen, Per Thayssen, et al.

    Aims Reporting of quantitative myocardial blood flow (MBF) is typically performed in standard coronary territories. However, coronary anatomy and myocardial vascular territories vary among individuals, and a coronary artery may erroneously be deemed stenosed or not if territorial demarcation is incorrect. So far, the diagnostic consequences of calculating individually vs. standardly assessed MBF values have not been reported. We examined whether individual reassignment of vascular territories would improve the diagnostic accuracy of MBF with regard to the detection of significant coronary artery disease (CAD). Methods and results Forty-four patients with suspected CAD were included prospectively and underwent coronary CT-angiography and quantitative MBF assessment with O-15-water PET followed by invasive, quantitative coronary angiography, which served as reference. MBF was calculated in the vascular territories during adenosine stress according to a standardized 17-segment American Heart Association model and an individualized model, using CT-angiography to adjust the coronary territories to their feeding vessels. Individually defined territories deviated from standard territories in 52% of patients. However, MBF in the three coronary territories defined by standard and individualized models did not differ significantly, except in one patient, in whom the MBF of an individualized coronary territory deviated sufficiently as to change the test from a false positive to a true negative result in this particular territory. Conclusion Disparity between standardized and individualized vascular territories was present in half of the patients, but had little clinical impact. Still, caution should be taken not always to rely on standard territories, as this may at times cause misinterpretation.


  • Open Access

    Bone Scan Index predicts outcome in patients with metastatic hormone‐sensitive prostate cancer

    by Mads H. Poulsen, Janne Rasmussen, Lars Edenbrandt, Poul F. Høilund‐Carlsen, Oke Gerke, Allan Johansen, Lars Lund

    Objective: To evaluate the Bone Scan Index ( BSI ) for prediction of castration resistance and prostate cancer‐specific survival ( PCSS ). In this retrospective study, we used novel computer‐assisted software for automated detection/quantification of bone metastases by BSI . Patients with prostate cancer are M‐staged by whole‐body bone scintigraphy ( WBS ) and categorised as M0 or M1. Within the M1 group, there is a wide range of clinical outcomes. The BSI was introduced a decade ago providing quantification of bone metastases by estimating the percentage of bone involvement. Being too time consuming, it never gained widespread clinical use. Patients and Methods: In all, 88 patients with prostate cancer awaiting initiation of androgen‐deprivation therapy due to metastases were included. WBS was performed using a two‐headed γ‐camera. BSI was obtained using the automated platform EXINI bone ( EXINI Diagnostics AB , Lund, Sweden). In Cox proportional hazard models, time to castration‐resistant prostate cancer ( CRPC ) and PCSS were modelled as the dependent variables, whereas prostate‐specific antigen ( PSA ) level, Gleason score and BSI were used as explanatory factors. For Kaplan–Meier estimates, BSI groups were dichotomously split into: BSI <1 and BSI ≥1. Discrimination between prognostic models was explored using the concordance index (C‐index). Results: The mean (range) age of the patients was 72 (52–92) years, the median (range) PSA level was 73 (4–5 740) ng/mL, the mean (range) Gleason score was 7.7 (2–10), and the mean (range) BSI was 1.0 (0–9.2). During a mean (range) follow‐up of 26 (8–49) months, 48 patients became castration resistant and 15 had died; most (13) from prostate cancer. In multivariate analysis including PSA level, Gleason score and BSI , only prediction by BSI was statistically significant. This was true both for time to CRPC (hazard ratio [ HR ] 1.45, 95% confidence interval [ CI ] 1.22–1.74; C‐index increase from 0.49 to 0.69) and for PCSS ( HR 1.34, 95% CI 1.07–1.67; C‐index increase from 0.76 to 0.95). Conclusion: BSI obtained using a novel automated computer‐assisted algorithm appears to be a useful predictor of outcome for time to CRPC and PCSS in patients with hormone‐sensitive metastatic prostate cancer.